News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mesoblast Limited's Phase 2 Trial For Lumbar Spinal Fusion Selected For Presentation at Premier Spine Conference


9/19/2013 9:41:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MELBOURNE, Australia and NEW YORK, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the Phase 2 clinical trial using the Company's proprietary Mesenchymal Precursor Cells (MPCs) for lumbar spinal fusion has been selected for presentation at the North American Spine Society (NASS) 28th Annual Meeting.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES